Home | Beiträge | ECE 2021

Spotlight Discussions

ECE 2021

N. Reisch, H. Hoyer-Kuhn, M. Pavel

Endokrine Disruptoren

ECE 2021

N. Reisch, H. Hoyer-Kuhn, M. Pavel

Cushing-Syndrom - aktuelle Therapielandschaft

ECE 2021

N. Reisch, H. Hoyer-Kuhn, M. Pavel, H. Siggelkow

Sequenztherapie der Osteoporose

ECE 2021

N. Reisch, H. Hoyer-Kuhn, M. Pavel, H. Siggelkow

Neue Entwicklungen bei AGS-Therapie

ECE 2021

N. Reisch, H. Hoyer-Kuhn, M. Pavel, H. Siggelkow

Hypoparathyreodismus neu bewertet

Knochen- und Mineralstoffwechsel

ECE 2021

Prof. Dr. med. Heide Siggelkow

TransCon PTH as a potential hormone replacement therapy...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Safety, tolerability and pharmacodynamics of AZP-3601,...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Risk of chronic kidney disease and change in GFR in...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Cardiovascular events in adult patients with chronic...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Bone consequences of high dose denosumab to treat an...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Bisphosphonates after Denosumab withdrawal reduce the...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Challenges of hypoparathyroidism

ECE 2021

Prof. Dr. med. Heide Siggelkow

One year in bone

ECE 2021

Prof. Dr. med. Heide Siggelkow

News about hypophosphatasia

ECE 2021

Prof. Dr. med. Heide Siggelkow

AAV liver gene therapy-mediated inhibition of FGF23...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Quantifying the real-world clinical and economic burden...

ECE 2021

Prof. Dr. med. Heide Siggelkow

The effect of intra-operative autofluorescence...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Non-nuclear cataracts in hypoparathyroidism are...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Deficiency or insufficiency of vitamin D and the...

Bone and mineral metabolism

ECE 2021

Prof. Dr. med. Heide Siggelkow

TransCon PTH as a potential hormone replacement therapy...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Safety, tolerability and pharmacodynamics of AZP-3601,...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Risk of chronic kidney disease and change in GFR in...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Cardiovascular events in adult patients with chronic...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Bone consequences of high dose denosumab to treat an...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Bisphosphonates after Denosumab withdrawal reduce the...

ECE 2021

Prof. Dr. med. Heide Siggelkow

AAV liver gene therapy-mediated inhibition of FGF23...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Quantifying the real-world clinical and economic burden...

ECE 2021

Prof. Dr. med. Heide Siggelkow

The effect of intra-operative autofluorescence...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Non-nuclear cataracts in hypoparathyroidism are...

ECE 2021

Prof. Dr. med. Heide Siggelkow

Deficiency or insufficiency of vitamin D and the...

Nebenniere

ECE 2021

Prof. Dr. med. Nicole Reisch

Steroid metabolomics for the detection of malignancy in...

ECE 2021

Prof. Dr. med. Nicole Reisch

Neuroendocrine stress response at single cell...

ECE 2021

Prof. Dr. med. Nicole Reisch

Results of the ADIUVO trial, the first randomized study...

ECE 2021

Prof. Dr. med. Nicole Reisch

Pre-operative hypercortisolism and post-operative...

ECE 2021

Prof. Dr. med. Nicole Reisch

Fascin-1, a novel-circulating marker for the prognosis...

ECE 2021

Prof. Dr. med. Nicole Reisch

Primary results from MATCH: A randomised controlled...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Salivary steroid and 11‑oxygenated androgen profiles in...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Tildacerfont for the treatment of patients with classic...

ECE 2021

Prof. Dr. med. Nicole Reisch

Adverse events of mitotane treatment in patients with...

ECE 2021

Prof. Dr. med. Nicole Reisch

Novel treatment and monitoring options for CAH

Adrenal Endocrinology

ECE 2021

Prof. Dr. med. Nicole Reisch

Steroid metabolomics for the detection of malignancy in...

ECE 2021

Prof. Dr. med. Nicole Reisch

Neuroendocrine stress response at single cell...

ECE 2021

ECE 2021

Results of the ADIUVO trial, the first randomized study...

ECE 2021

Prof. Dr. med. Nicole Reisch

Primary results from MATCH: A randomised controlled...

ECE 2021

Prof. Dr. med. Nicole Reisch

Adverse events of mitotane treatment in patients with...

ECE 2021

Prof. Dr. med. Nicole Reisch

Novel treatment and monitoring options for CAH

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Salivary steroid and 11‑oxygenated androgen profiles in...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Tildacerfont for the treatment of patients with classic...

Hypophyse und Neuroendokrinologie

ECE 2021

Prof. Dr. med. Marianne Pavel

Osilodrostat, a potent oral 11β-hydroxylase inhibitor

ECE 2021

Prof. Dr. med. Marianne Pavel

Osilodrostat provides sustained control of urinary free...

ECE 2021

Prof. Dr. med. Marianne Pavel

Metyrapone treatment in endogenous Cushing’s syndrome....

ECE 2021

Prof. Dr. med. Marianne Pavel

A Phase 3 Large International Noninferiority Trial...

ECE 2021

Prof. Dr. med. Marianne Pavel

Addition of cabergoline to oral octreotide capsules may...

ECE 2021

Prof. Dr. med. Marianne Pavel

Identification of a dose range for once daily oral...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

GH replacement in adults

ECE 2021

Prof. Dr. med. Marianne Pavel

Thymic neuroendocrine tumor and mortality in MEN 1...

ECE 2021

Prof. Dr. med. Marianne Pavel

Reassessment of the diagnostic criteria of insulinoma:...

ECE 2021

Prof. Dr. med. Marianne Pavel

Can the follow-up imaging interval for non-functioning...

Pituitary and Neuroendocrinology

ECE 2021

Prof. Dr. med. Marianne Pavel

Osilodrostat, a potent oral 11β-hydroxylase inhibitor

ECE 2021

Prof. Dr. med. Marianne Pavel

Osilodrostat provides sustained control of urinary free...

ECE 2021

Prof. Dr. med. Marianne Pavel

A Phase 3 Large International Noninferiority Trial...

ECE 2021

Prof. Dr. med. Marianne Pavel

Addition of cabergoline to oral octreotide capsules may...

ECE 2021

Prof. Dr. med. Marianne Pavel

Identification of a dose range for once daily oral...

Reproduktion und Entwicklung

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Long-term effects of testosterone replacement therapy

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Non-contraceptive therapeutic use of combined oral...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Effect of IL-1 receptor antagonism on hyperandrogenemia...

Reproduction and Development

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Effect of IL-1 receptor antagonism on hyperandrogenemia...

Varia

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

COVID-19 and hormones – the role of Endocrinologists in...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Endocrine Disruptors - a key challenge for...

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Monogenic variants in the Finnish Pediatric Diabetes...

Varia

ECE 2021

PD Dr. med. Heike Hoyer-Kuhn

Monogenic variants in the Finnish Pediatric Diabetes...